Portola Pharmaceuticals, Inc. announced launch of Ondexxya with first orders in Europe. CMS increased maximum NTAP reimbursement for Andexxa from 50% to 65% effective on October 1, 2019. The company presented new Andexxa data from a subset of patients from the ANNEXA-4 study with spontaneous (non-traumatic) intracranial hemorrhage, which demonstrated excellent or good hemostasis achieved in 79% of evaluable patients. The company presented in vitro data demonstrating that four-factor prothrombin complex concentrate (4F-PCC) does not appear to have an effect on the inhibition of thrombin generation by apixaban or rivaroxaban unless the Factor Xa inhibitor concentration was less than 75 ng/mL. In contrast, data from the same thrombin generation assay demonstrated that Andexxa fully corrected the inhibition of thrombin generation by apixaban and rivaroxaban across a broad range of inhibitor concentrations. Presented new interim results from the cerdulatinib Phase 2a study demonstrating favorable safety and efficacy profiles in patients with relapsed/refractory follicular lymphoma (FL) receiving cerdulatinib alone (45% objective response rate) or in combination with rituximab (62% objective response rate). The company continue launch of Ondexxya in a select group of high-potential European countries where Factor Xa inhibitor use is among the highest. The company plan to initiate surgical study for Andexxa label expansion by year end or beginning of 2020. The company announced launch of a cerdulatinib registrational study in peripheral T-cell lymphoma (PTCL) by the end of the year. The company present new data from additional subsets of the ANNEXA-4 study.